Anzeige
Mehr »
Login
Montag, 20.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
100-Milliarden-Dollar-Marke: Wie die strategische Vision eines Unternehmens historischem Meilenstein passt!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
Actusnews Wire
555 Leser
Artikel bewerten:
(2)

OL GROUPE: CO-OPTATION OF NEW DIRECTORS

Finanznachrichten News

CO-OPTATION OF NEW DIRECTORS

Lyon, October 3, 2023.

The Board of Directors, during its meeting held on 6 September, acknowledged the resignations of Annie Famose, Héloïse Deliquiet, Sidonie Mérieux, Pauline Boyer-Martin and Annie Bouvier, as well as Durcesio Mello, and the Board of Directors held on 28 September 2023, has also acknowledged the resignations of Ron Friedman and Alexander Bafer.

These resignations occur in the context of a recomposition of the Board of Directors and reduction of the total number of its members following the tender offer initiated by Eagle Football Holding Bidco Limited and closed on 2 August 2023.

The Company would like to thank these directors for their involvement and work, some of them during several years, for the benefit of the Olympique Lyonnais group.

As mentioned in the press release dated 7 September 2023, the Board of Directors co-opted Michele Kang on 6 September 2023. The Board of Directors continued the co-optations during its meeting held on 28 September 2023 through the co-optation of Bethel Gottlieb and Deborah Andrews, independent directors, to replace Héloïse Deliquiet and Pauline Boyer-Martin respectively, for the remainder of their predecessor's term of office (i.e. until the General Meeting called to approve the financial statements for the year ending 30 June 2028 and 30 June 2026 respectively). These co-optations will be submitted to shareholders for ratification at the next General Meeting.

The other resigning directors have not been replaced.

As a result, the Board of Directors acknowledged during its meeting held on 3 October 2023 that it comprises 12 directors, including:

• 5 women, representing 42% of the directors; and

• 5 independent directors, representing 42% of the directors[1].

The Board has ensured that such composition provides it with all the skills it needs to operate properly and to carry out its mission of defining the strategy of OL Groupe and overseeing its implementation.

XXX

About Bethel Gottlieb

Ms. Gottlieb is an active investor, director and advisor, focused on both corporate and philanthropic activities. Her professional career included senior merchandising management positions, for firms such as May Department Stores and Federated Department Stores. Subsequent to her career in merchandising, she became a principal investor through Wyndcrest Holdings, a private holding company responsible for several notable technology-related investments in entertainment, telecommunications and the Internet.

About Deborah Andrews

Ms. Andrews brings over 20 years of technology solution and sales experience in the fields of Health Care and Digital Innovation. Her professional journey has encompassed organizations such as Time Warner, Experian Marketing Services, Pitney Bowes, and Precisely, before joining Smart Communications in December 2021 where she leads the Smart IQ and Health Care sales teams. Deborah has played a pivotal role notably in the adoption and integration of digital communication software technologies.essentiel, notamment dans l'adoption et l'intégration





Tel: +33 (0)4 81 07 55 00
Fax: +33 (0)4 81 07 45 65

Email: investisseurs@ol.fr

www.ol.fr

Euronext Paris - Segment C

Indices: CAC Small - CAC Mid & Small - CAC All-Tradable - CAC All-Share - CAC Consumer Discretionary
ISIN code: FR0010428771
Reuters: OLG.PA
Bloomberg: OLG FP
ICB: 40501030 Recreational services

[1] The Board of Directors considers that the following directors meet the independence criteria set out in the AFEP-MEDEF Code and the Company's Board internal rules: Nathalie Dechy, Camille Lagache, Bethel Gottlieb, Deborah Andrews and Shahrad Tehranchi.

------------------------
This publication embed "Actusnews SECURITY MASTER".
- SECURITY MASTER Key: mJyfY5WalmrHyJ6el5ZomWGYbmiUlpWWZWKcmmFplZrFnHBjypmXZ5acZnFjlmxn
- Check this key: https://www.security-master-key.com.
------------------------
Full and original release in PDF format:
https://www.actusnews.com/documents_communiques/ACTUS-0-82171-olg-03102023-cooptation-en.pdf

© Copyright Actusnews Wire
Receive by email the next press releases of the company by registering on www.actusnews.com, it's free
© 2023 Actusnews Wire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.